Gilead Sciences Inc. recently disclosed details on the work that led to the discovery of elunonavir (GS-1156), an unboosted HIV protease inhibitor currently in phase I studies.
Weight gain associated with integrase strand transfer inhibitor-based antiretroviral therapy (ART) may be mitigated or reversed over time by switching to protease inhibitor-based ART. For patients ...
As of today, the central role of mitochondrial metabolism associated with tumorigenesis and progression of malignancies has been deeply investigated. Moreover, oxidative phosphorylation inhibition ...
New guidelines update ART choices, endorse long-acting injectables, refine infant feeding advice, and prioritise shorter TB ...
NEW YORK (Reuters) - Johnson & Johnson said on Tuesday its drug Prezista was as effective in a late-stage trial as Abbott Laboratories Inc's Kaletra in cutting HIV to undetectable levels among ...
Despite these constraints, the investigators concluded that the results reinforce current perinatal HIV treatment ...
The development of new classes of antiretroviral drugs, such as integrase inhibitors and CCR5-antagonistic entry inhibitors, has opened the possibility of considering regimens without NRTIs (Table 1).
As people with HIV age, their risk of heart attack increases far more if they also have untreated hepatitis C virus, even if their HIV is treated, according to new research published today in the ...
Astrazeneca AB has disclosed CX3C chemokine receptor 1 (CX3CR1; CMKBRL1; GPR13) antagonists reported to be useful for the treatment of heart failure, among others. AC Immune SA has landed a potential ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results